Evidence map›Paper›PMID 31884570›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2020

Agonist-specific desensitization of PGE

Francisco J Nunez, Nancy A Schulte, David M Fogel, Joel Michalski, Stephen I Rennard, Raymond B Penn, Myron L Toews, Rennolds S Ostrom

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Mechanistic basis for the antifibrotic actions of cAMP-based therapies.European respiratory review : an official journal of the European Respiratory Society · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. In silico identification of a βProceedings of the National Academy of Sciences of the United States of America · 2022
    Article
  7. Article
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Francisco J NunezDepartment of Biomedical and Pharmaceutical Sciences, Chapman University School of Pharmacy, Irvine, CA, 92672, USA.
Nancy A SchulteDepartment of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, USA.
David M FogelDepartment of Biomedical and Pharmaceutical Sciences, Chapman University School of Pharmacy, Irvine, CA, 92672, USA.
Joel MichalskiDepartment of Internal Medicine, Section of Critical Care and Sleep Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
Stephen I RennardDepartment of Internal Medicine, Section of Critical Care and Sleep Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
Raymond B PennDivision of Pulmonary and Critical Care Medicine, Department of Medicine, Center for Translational Medicine, The Jane & Leonard Korman Respiratory Institute, Thomas Jefferson University, Philadelphia, PA, USA.
Myron L ToewsDepartment of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, USA.
Rennolds S OstromDepartment of Biomedical and Pharmaceutical Sciences, Chapman University School of Pharmacy, Irvine, CA, 92672, USA. rostrom@chapman.edu.ORCID 0000-0002-7204-0357
University of Nebraska Medical Center · USChapman University · USThomas Jefferson University · US

Funding

G Protein-Coupled Receptor Signaling in Airway Smooth MuR01HL058506 · NHLBI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI RAYMOND B. PENN · 2001 to 2026
$9.3M
Molecular signal transduction of cAMP compartmentsR01GM107094 · NIGMS · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI OSTROM, RENNOLDS S · 2015 to 2022
$2.3M
Optimizing EP receptor subtype targeting for asthma therapyR01HL136209 · NHLBI · THOMAS JEFFERSON UNIVERSITY · PI BIRRELL, MARK A, BOYCE, JOSHUA A · 2017 to 2020
$2.2M
BETA ADRENERGIC RECEPTOR REGULATION IN HUMAN AIRWAY MUSCR29HL058506 · NHLBI · THOMAS JEFFERSON UNIVERSITY · PI PENN, RAYMOND B. · 1997 to 2000
$113k
NHLBI NIH HHS R01 HL058506NHLBI NIH HHS R01 HL136209NHLBI NIH HHS R29 HL058506NIGMS NIH HHS R01 GM107094
6 · The paper itself

Abstract

Pulmonary fibrosis is characterized by fibroblasts persisting in an activated form, producing excessive fibrous material that destroys alveolar structure. The second messenger molecule cyclic 3',5'-adenosine monophosphate (cAMP) has antifibrotic properties, and prostaglandin E

Indexed as

Cells, CulturedCyclic AMPDinoprostoneDose-Response Relationship, DrugFibroblastsHumansIsoenzymesLungPhosphoric Diester HydrolasesPulmonary FibrosisReceptors, Prostaglandin E, EP2 SubtypeSecond Messenger SystemsUp-RegulationCyclic AMPDinoprostoneIsoenzymesPhosphoric Diester HydrolasesPTGER2 protein, humanReceptors, Prostaglandin E, EP2 SubtypecAMPEP2 receptorsPGE2PhosphodiesterasePulmonary fibrosis

Identifiers

PMID31884570
PMCPMC7328663
OpenAlexW2997998804

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.